Greenleaf Trust decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 13.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,419 shares of the medical research company’s stock after selling 1,167 shares during the period. Greenleaf Trust’s holdings in Amgen were worth $1,129,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Tiemann Investment Advisors LLC purchased a new position in shares of Amgen during the first quarter valued at about $226,000. Badgley Phelps & Bell Inc. boosted its position in shares of Amgen by 12.1% in the first quarter. Badgley Phelps & Bell Inc. now owns 28,150 shares of the medical research company’s stock valued at $4,221,000 after buying an additional 3,048 shares during the period. Compton Capital Management Inc. RI boosted its position in shares of Amgen by 1.5% in the first quarter. Compton Capital Management Inc. RI now owns 6,060 shares of the medical research company’s stock valued at $909,000 after buying an additional 90 shares during the period. Northern Oak Wealth Management Inc. boosted its position in shares of Amgen by 8.5% in the first quarter. Northern Oak Wealth Management Inc. now owns 33,774 shares of the medical research company’s stock valued at $5,064,000 after buying an additional 2,640 shares during the period. Finally, Bowling Portfolio Management LLC boosted its position in shares of Amgen by 46.5% in the first quarter. Bowling Portfolio Management LLC now owns 61,778 shares of the medical research company’s stock valued at $9,262,000 after buying an additional 19,600 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ:AMGN) traded down 1.45% during midday trading on Friday, hitting $161.90. The stock had a trading volume of 2,817,469 shares. The company’s 50 day moving average is $169.59 and its 200 day moving average is $162.28. Amgen Inc. has a 1-year low of $139.02 and a 1-year high of $176.85. The company has a market cap of $121.16 billion, a price-to-earnings ratio of 16.57 and a beta of 0.94.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The company earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same period in the prior year, the business posted $2.57 EPS. The company’s quarterly revenue was up 5.9% on a year-over-year basis. On average, equities analysts anticipate that Amgen Inc. will post $11.35 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 8th. Stockholders of record on Wednesday, November 16th will be paid a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.47%. Amgen’s dividend payout ratio is 40.90%.
AMGN has been the topic of several research analyst reports. Jefferies Group reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, September 28th. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $188.11 price target on the stock in a research report on Thursday, September 29th. Robert W. Baird reiterated an “outperform” rating and set a $157.00 price target on shares of Amgen in a research report on Friday, August 26th. Gabelli initiated coverage on Amgen in a research report on Friday, August 26th. They set a “hold” rating on the stock. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $190.00 price target on shares of Amgen in a research report on Thursday, September 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. Amgen currently has an average rating of “Buy” and an average price target of $184.94.
In other news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.